McKesson Health Solutions has introduced InterQual® 2015, the latest edition of the company’s decision-support solution.
The release has 55 new and enhanced evidence-based clinical content areas and extensive updates — including the industry’s first admissions criteria to include comorbidities, criteria for 29 new specialty drugs and 33 new molecular diagnostic tests, plus support for gene panels, and much more.
“With InterQual 2015, we’re helping ensure payers and providers have the evidence-based content they need for the challenges they face today — such as the increase in patients with comorbidities — so they can ensure the most appropriate decisions and highest quality care,” said Jackie Mitus, MD, senior vice president and general manager of decision management for McKesson Health Solutions.
InterQual 2015’s Specialty Rx Criteria now covers 88% of the top 25 medical benefit specialty drugs, the company said. The Multi-Gene Panel for Inherited Breast Cancer also is one of the 33 new tests covered in InterQual 2015’s Molecular Diagnostics (MDx) Criteria update.
Additionally, InterQual 2015’s Home Care Criteria has been transformed into a question-and-answer format. Other enhancements include improvements to InterQual’s CareEnhance Review Manager and InterQual Mobile for iOS and Android.
